Literature DB >> 9128999

The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors.

N Younes1, N Fulton, R Tanaka, J Wayne, F H Straus, E L Kaplan.   

Abstract

BACKGROUND: Adenocarcinomas and carcinoid tumors are the most common malignant tumors of the small intestine. K-ras oncogene mutations at codon 12 are common in gastric, pancreatic, and colon carcinomas, with an incidence of 35-88%. K-ras mutations have not been extensively studied in either adenocarcinomas or carcinoid tumors of the small bowel. The purpose of this study was to determine whether ras mutations play an important role in the formation of these tumors.
METHODS: Archival tissues from 28 adenocarcinomas and 22 carcinoid tumors of the small bowel were studied, along with archival tissues from 32 adenocarcinomas of the large bowel, which were used as controls. DNA from the small intestine tumors was analyzed for K-ras, H-ras, and N-ras oncogene mutations at codons 12, 13, and 61, using polymerase chain reaction and sequence specific oligonucleotide hybridization techniques. Large bowel adenocarcinomas were analyzed for K-ras mutations at codons 12 and 13.
RESULTS: A point mutation of K-ras at codon 12 was detected in 4 of 28 (14.3%) of the small bowel adenocarcinomas, in 12 of 32 (37.5%) of the large bowel adenocarcinomas, and in 0 of 22 small intestine carcinoid tumors. No other K-ras, H-ras, or N-ras mutations were detected in any of the small bowel tumors. Each small intestine K-ras mutation was found in a duodenal adenocarcinoma (4 of 12 cases, 33%), whereas none occurred in 16 other jejunal or ileal adenocarcinomas.
CONCLUSIONS: K-ras mutations appear to play a significant role in the pathogenesis of duodenal adenocarcinomas, but they do not appear to be important in the development of jejunal or ileal adenocarcinomas or of carcinoid tumors of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9128999

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas.

Authors:  T Muneyuki; M Watanabe; M Yamanaka; S Isaji; Y Kawarada; R Yatani
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

2.  Frequent Ki-ras mutations and transforming growth factor-alpha expression in adenocarcinomas of the small intestine: report of 7 cases.

Authors:  Hiroyuki Mitomi; Takatoshi Nakamura; Atsushi Ihara; Yoshimasa Otani; Miwa Sada; Masahiro Igarashi; Fumiyuki Akino; Masaaki Ichinoe; Tatsuya Ojima; Akio Mori; Isao Okayasu
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

Review 3.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

4.  Morphological-histochemical study of intestinal carcinoids and K-ras mutation analysis in appendiceal carcinoids.

Authors:  H Paraskevakou; A Saetta; K Skandalis; S Tseleni; A Athanassiadis; P S Davaris
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  An insight into the genetic pathway of adenocarcinoma of the small intestine.

Authors:  J M D Wheeler; B F Warren; N J McC Mortensen; H C Kim; S C Biddolph; G Elia; N E Beck; G T Williams; N A Shepherd; A C Bateman; W F Bodmer
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.

Authors:  Sun-Young Jun; Misung Kim; Mi Jin Gu; Young Kyung Bae; Hee-Kyung Chang; Eun Sun Jung; Kee-Taek Jang; Jihun Kim; Eunsil Yu; Dae Woon Eom; Seung-Mo Hong
Journal:  Mod Pathol       Date:  2016-02-19       Impact factor: 7.842

7.  A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.

Authors:  Kyle M Walsh; Murim Choi; Kjell Oberg; Matthew H Kulke; James C Yao; Chengqing Wu; Magdalena Jurkiewicz; Ling-I Hsu; Susanne M Hooshmand; Manal Hassan; Eva T Janson; Janet L Cunningham; Evan Vosburgh; Richard S Sackler; Richard P Lifton; Andrew T Dewan; Josephine Hoh
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

8.  KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.

Authors:  Tao Fu; Angela A Guzzetta; Jana Jeschke; Rajita Vatapalli; Pujan Dave; Craig M Hooker; Richard Morgan; Christine A Iacobuzio-Donahue; Baohua Liu; Nita Ahuja
Journal:  Int J Cancer       Date:  2013-01-18       Impact factor: 7.396

9.  ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line.

Authors:  Dustin Deming; Peter Geiger; Herbert Chen; Abram Vaccaro; Muthusamy Kunnimalaiyaan; Kyle Holen
Journal:  J Gastrointest Surg       Date:  2008-05       Impact factor: 3.452

Review 10.  Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Authors:  Chad M Thompson; Deborah M Proctor; Mina Suh; Laurie C Haws; Christopher R Kirman; Mark A Harris
Journal:  Crit Rev Toxicol       Date:  2013-03       Impact factor: 5.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.